South African tycoon Stephen Saad’s Aspen stake loses $18 million
Stephen Saad’s Aspen stake drops $18 million as shares fall 5.45% in 16 days, deepening losses for South Africa’s largest drugmaker.
Skip to content
Stephen Saad’s Aspen stake drops $18 million as shares fall 5.45% in 16 days, deepening losses for South Africa’s largest drugmaker.
Stephen Saad’s Aspen wins $29 million settlement in mRNA production dispute, boosting investor confidence after a tough fiscal year.
South African businessman Gus Attridge’s stake in Aspen Pharmacare rebounds above $100 million as the company’s shares recover on the JSE.
Gus Attridge’s Aspen Pharmacare stake drops over $12 million as shares slide 9.45%, pushing market value below $3 billion.
Shares of Aspen Pharmacare plunged 5.44 percent in a week, wiping millions off co-founder Gus Attridge’s stake.
His 19,188,850 shares are now valued at R3.24 billion ($175.82 million), reflecting the latest decline in Aspen’s stock price.
This follows a $12 million gain recorded between April 23 and May 3, when his stake rose from R4.07 billion ($219.65 million) to R4.29 billion ($231.65 million).
Futurelife was founded in 2007 by Saad, the brother of South African billionaire Stephen Saad, who serves as the CEO of Aspen Pharmacare Holdings.
Saad, who founded Aspen Pharmacare Holdings in 1997, owns a 12.5-percent stake in the branded pharmaceutical company.
Aspen Pharmacare Holdings is a South African multinational pharmaceutical holding company.